News & Articles

BioCity, Breakfast and IP for Medical Diagnostics

BioCity, Breakfast and IP for Medical Diagnostics
Thursday, February 15th, 2018 / no comments / , ,

BioCity Scotland is hosting an IP breakfast seminar on 21st February 2018 and Ellis IP is delighted to be collaborating with BioCity to deliver it. This event is open to all – please register here:

Our own Dr Claudia Duffy will provide a general review of IP rights and filing strategies based on UK, EU and US laws. Dr Michael Ellis will discuss the patentability of diagnostic and medical treatments. The schedule is to be as follows:

9:00 – 10:00
Breakfast and networking over coffee

10:00 – 10:30
IP rights (IPRs) and filing strategies based on UK, EU and US laws; understanding your competition

Knowing what types of IPRs are required by a company in order (i) to protect its initial key innovation and (ii) to secure investment is a major consideration which should be addressed by businesses from the outset, often before company formation.

Moreover, choosing the markets for commercialising the innovation is another factor determining the geographical coverage of the IPRs. And, as with most businesses formed in the UK, Europe and the USA are key territories to be considered by the business when developing a long-term IP strategy.

Likewise, understanding the restrictions imposed or the opportunities afforded by the competitors’ IPRs should be carefully weighed when considering the freedom to operate and the development of their product. For instance, often it might be more beneficial for a business to seek a licence deal rather than to invent around a competitor’s IPR.

10:30 – 11:00
Patentability of Diagnostics and Medical Treatments

Patent eligibility for diagnostic products is a major problem for life science innovators following US Supreme Court rulings (Mayo, Myriad, Alice) and changes in practice by the USPTO. How do you prevent competitors simply adopting your technology and on what basis can you agree a licence? Here we explore what will and what will not be deemed patent eligible in the US, what you may want to think about to improve your position in the US (e.g. when filing a new application) and the options available if you have pending patent. We will compare the position in Europe and other territories.

We look forward to seeing you there.